Karthik Venkatakrishnan
Overview
Explore the profile of Karthik Venkatakrishnan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
156
Citations
1997
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kareva I, Hu P, Pierre V, Kitzing T, Victor A, Richter E, et al.
Clin Pharmacol Ther
. 2025 Feb;
PMID: 39921877
Refining dose projections requires a deep understanding of drug-target relationships at the site of action, which is often challenging to achieve. Here we present a case study of how one...
2.
Liu H, Ibrahim E, Centanni M, Sarr C, Venkatakrishnan K, Friberg L
Adv Drug Deliv Rev
. 2024 Nov;
216:115476.
PMID: 39577694
Model-based approaches, including population pharmacokinetic-pharmacodynamic modeling, have become an essential component in the clinical phases of oncology drug development. Over the past two decades, models have evolved to describe the...
3.
Lu H, Klopp-Schulze L, Mukker J, Li D, Kuroki Y, Bolleddula J, et al.
Clin Transl Sci
. 2024 Oct;
17(10):e70050.
PMID: 39445632
With the International Conference on Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) E17 guidelines in effect from 2018, the design of Asia-inclusive multiregional clinical trials (MRCTs) has...
4.
Izat N, Bolleddula J, Carione P, Huertas Valentin L, Jones R, Kulkarni P, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Oct;
14(1):164-178.
PMID: 39444174
Aldehyde oxidase (AO) contributes to the clearance of many approved and investigational small molecule drugs, which are often dual substrates of AO and drug-metabolizing enzymes such as cytochrome P450s (CYPs)....
5.
Starling M, Kehoe L, Burnett B, Green P, Venkatakrishnan K, Madabushi R
Clin Pharmacol Ther
. 2024 Oct;
117(2):343-352.
PMID: 39410710
While some model-informed drug development frameworks are well recognized as enabling clinical trials, the value of disease progression modeling (DPM) in impacting medical product development has yet to be fully...
6.
Yap T, Bullock J, Chong S, Doyle M, Hussain A, Kline J, et al.
Clin Cancer Res
. 2024 Oct;
30(23):5237-5241.
PMID: 39365679
The Project Optimus initiative from the FDA introduced a new dose optimization and selection paradigm in oncology drug development. The FDA has outlined approaches to dose optimization for single agents,...
7.
Amato F, Strotmann R, Castello R, Bruns R, Ghori V, Johne A, et al.
Clin Transl Sci
. 2024 Sep;
17(9):e70010.
PMID: 39222377
Tepotinib is approved for the treatment of patients with non-small-cell lung cancer harboring MET exon 14 skipping alterations. While edema is the most prevalent adverse event (AE) and a known...
8.
Minichmayr I, Shebley M, van der Graaf P, Venkatakrishnan K
Clin Pharmacol Ther
. 2024 Aug;
116(3):491-496.
PMID: 39164848
No abstract available.
9.
Milenkovic-Grisic A, Hayes S, Farrell C, Kuroki Y, Bertolino M, Venkatakrishnan K, et al.
Clin Pharmacol Ther
. 2024 Aug;
116(4):1071-1081.
PMID: 39132970
Cetuximab was initially developed and approved as a first-line treatment in patients with unresectable metastatic colorectal cancer (mCRC) for weekly administration (250 mg/m Q1W with 400 mg/m loading dose). An...
10.
Venkatakrishnan K, Jayachandran P, Seo S, van der Graaf P, Wagner J, Gupta N
Clin Transl Sci
. 2024 Jun;
17(6):e13859.
PMID: 38923292
No abstract available.